AEON Biopharma, Inc.

AEON

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001104659-26-024231
Filing date: Mar 5, 2026
Earliest execution date: Feb 17, 2026

Summary

Type

Neutral

Net shares

+1,500,925

% of shares

597978.09%

Amount (USD)

$0

Insider confidence score

90.0 out of 100

Positive

  • Massive buy (≥10% of shares)

Negative

  • Minimal buy amount (<$10K)

Stock transactions

Transaction 1

Security

Class A Common Stock

Action

Grant

Date

2026-02-17

Code

A

Net shares

+575,000.0

Acquired/Disposed

Acquired

Shares Owned Before

251.0

Shares Owned After

575,251.0

Transaction 2

Security

Class A Common Stock

Action

Grant

Date

2026-03-04

Code

A

Net shares

+925,925.0

Acquired/Disposed

Acquired

Shares Owned Before

575,251.0

Shares Owned After

1,501,176.0

Filing's footnotes

1. Represents an award of restricted stock units granted on February 17, 2026 (the &quot;Grant Date&quot;), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

2. Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the &quot;Grant Date&quot;) that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.